Associations - Pancreatic Ductal Adenocarcinoma

CANCER:

Pancreatic Ductal Adenocarcinoma

Related cancers:

‹

Pancreatic Cancer (256)

Pancreatic Adenocarcinoma (37)

Pancreatic Cancer (256)

Pancreatic Adenocarcinoma (37)

›

No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	SBP-101 Sensitive: B - Late Trials SBP-101 Sensitive : B
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: B - Late Trials gemcitabine Sensitive : B
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + capecitabine Sensitive: B - Late Trials gemcitabine + capecitabine Sensitive : B
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
HGF-H HGF-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials FOLFIRINOX Resistant : C3
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
BRCA1 mutation + BRCA2 mutation BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
FANCF mutation FANCF mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
MSH2 mutation MSH2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
DDR DDR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
C3M/PRO-C3 ratio elevation C3M/PRO-C3 ratio elevation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PEGPH20 Sensitive: C3 – Early Trials PEGPH20 Sensitive : C3
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	leucovorin calcium Resistant: C3 – Early Trials leucovorin calcium Resistant : C3
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	5-fluorouracil Resistant: C3 – Early Trials 5-fluorouracil Resistant : C3
GATA6 expression GATA6 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3
LAMC2 overexpression LAMC2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES